A Phase II Clinical Study to Evaluate the Tolerability, Safety, and Preliminary Efficacy of Intravesical Administration of Herpes Virus T3011 Injection in Participants With BCG-unresponsive High Risk Non-muscle-invasive Bladder Cancer
Latest Information Update: 20 May 2025
At a glance
- Drugs T 3011 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immvira Pharma
Most Recent Events
- 20 May 2025 New trial record